

## DAFTAR PUSTAKA

- BASTIAENS, M., HOEFNAGEL, J., WESTENDORP, R., VERMEER, B.-J. & BOUWES BAVINCK, J. N. 2004. Solar Lentigines are Strongly Related to Sun Exposure in Contrast to Ephelides. *Pigment Cell Research*, 17, 225-229.
- BATCHULUUN, B., INOGUCHI, T., SONODA, N., SASAKI, S., INOUE, T., FUJIMURA, Y., MIURA, D. & TAKAYANAGI, R. 2014. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD (P) H oxidase pathway in human aortic endothelial cells. *Atherosclerosis*, 232, 156-164.
- BLOUGH, B., MORELAND, A. & MORA, A., JR. 2015. Metformin-induced lactic acidosis with emphasis on the anion gap. *Proceedings (Baylor University Medical Center)*, 28, 31-33.
- BOLOGNIA, J. L. & PAWELEK, J. M. 1988. Biology of hypopigmentation. *Journal of the American Academy of Dermatology*, 19, 217-255.
- BRAY GA, EDELSTEIN SL, CRANDALL JP, ARODA VR, FRANKS PW, FUJIMOTO W, HORTON E, JEFFRIES S, MONTEZ M, MUDALIAR S, PI-SUNYER FX, WHITE NH & KNOWLER WC 2012. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. *Diabetes Care*, 35, 731-7.
- CHANNAKESHAVIAIAH, R. B. & CHANDRAPPA, N. K. A. 2020. Topical metformin in the treatment of melasma: A preliminary clinical trial. *Journal of Cosmetic Dermatology*, 19, 1161-1164.
- CLARYS, P., ALEWAETERS, K., LAMBRECHT, R. & BAREL, A. 2000. Skin color measurements: comparison between three instruments: the Chromameter®,

- the DermaSpectrometer® and the Mexameter®. *Skin research and technology*, 6, 230-238.
- DE DORMAEL, R., BASTIEN, P., SEXTIUS, P., GUENICHE, A., YE, D., TRAN, C., CHEVALIER, V., GOMES, C., SOUVERAIN, L. & TRICAUD, C. 2019. Vitamin C Prevents Ultraviolet-induced Pigmentation in Healthy Volunteers: Bayesian Meta-analysis Results from 31 Randomized Controlled versus Vehicle Clinical Studies. *The Journal of clinical and aesthetic dermatology*, 12, E53.
- DEL BINO, S. & BERNERD, F. 2013. Variations in skin colour and the biological consequences of ultraviolet radiation exposure. *British Journal of Dermatology*, 169, 33-40.
- DEL BINO, S., SOK, J., BESSAC, E. & BERNERD, F. 2006. Relationship between skin response to ultraviolet exposure and skin color type. *Pigment cell research*, 19, 606-614.
- DIFFEY, B. L. 2002. What is light? *Photodermatology, photoimmunology & photomedicine*, 18, 68-74.
- DUTEIL, L., ESDAILE, J., MAUBERT, Y., CATHELINEAU, A. C., BOULOC, A., QUEILLE-ROUSSEL, C. & PASSERON, T. 2017. A method to assess the protective efficacy of sunscreens against visible light-induced pigmentation. *Photodermatology, photoimmunology & photomedicine*, 33, 260-266.
- HECKMAN, C. J., CHANDLER, R., KLOSS, J. D., BENSON, A., ROONEY, D., MUNSHI, T., DARLOW, S. D., PERLIS, C., MANNE, S. L. & OSLIN, D. W. 2013. Minimal erythema dose (MED) testing. *JoVE (Journal of Visualized Experiments)*, e50175.
- JAUNE, E. & ROCCHI, S. 2018. Metformin: Focus on Melanoma. *Frontiers in endocrinology*, 9, 472-472.

- KENNEDY, M. S. N. & MASHARANI, U. 2014. Pancreatic Hormones & Antidiabetic Drugs. In: KATZUNG, B. G. & TREVOR, A. J. (eds.) *Basic & Clinical Pharmacology, Thirteenth Edition*, . New York: McGraw-Hill Education.
- KIM, G. H., CHEONG, K. A. & LEE, A.-Y. 2017. Increased Skin Irritation by Hydroquinone and Retinoic Acid Used in Combination. *Annals of dermatology*, 29, 715-721.
- LASHEN, H. 2010. Role of metformin in the management of polycystic ovary syndrome. *Therapeutic advances in endocrinology and metabolism*, 1, 117-128.
- LEE, A. Y. 2015. Recent progress in melasma pathogenesis. *Pigment Cell Melanoma Res*, 28, 648-60.
- LEHRAIKI, A., ABBE, P., CEREZO, M., ROUAUD, F., REGAZZETTI, C., CHIGNON-SICARD, B., PASSERON, T., BERTOLOTTO, C., BALLOTTI, R. & ROCCHI, S. 2014. Inhibition of melanogenesis by the antidiabetic metformin. *Journal of Investigative Dermatology*, 134, 2589-2597.
- MADDODI, N., JAYANTHY, A. & SETALURI, V. 2012. Shining light on skin pigmentation: the darker and the brighter side of effects of UV radiation. *Photochemistry and photobiology*, 88, 1075-1082.
- MAPAR, M. A., HEMMATI, A. A. & NAMDARI, G. 2019. Comparing the Efficacy of Topical Metformin and Placebo in the Treatment of Melasma: A Randomized, Double-blind, Clinical Trial. *Journal of Pharmaceutical Research International*, 1-8.
- MATSUBAYASHI, T., SAKAEDA, T., KITA, T., KURIMOTO, Y., NAKAMURA, T., NISHIGUCHI, K., FUJITA, T., KAMIYAMA, F., YAMAMOTO, A. & OKUMURA, K. 2003. Intradermal concentration of hydroquinone after application of

- hydroquinone ointments is higher than its cytotoxic concentration. *Biological and Pharmaceutical Bulletin*, 26, 1365-1367.
- MAYMONE, M. B. C., NEAMAH, H. H., WIRYA, S. A., PATZELT, N. M., SECEMSKY, E. A., ZANCANARO, P. Q. & VASHI, N. A. 2017. The impact of skin hyperpigmentation and hyperchromia on quality of life: A cross-sectional study. *Journal of the American Academy of Dermatology*, 77, 775-778.
- MILLER, R. A., CHU, Q., XIE, J., FORETZ, M., VIOLLET, B. & BIRNBAUM, M. J. 2013. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. *Nature*, 494, 256.
- OSTROWSKI, S. M. & FISHER, D. E. 2019. Pigmentation and Melanocyte Biology. *In: KANG, S., AMAGAI, M., BRUCKNER, A. L., ENK, A. H., MORGOLIS, D. J., MCMICHAEL, A. J. & ORRINGER, J. S. (eds.) Fitzpatrick's Dermatology 9th Ed.* McGraw-Hill Education.
- PLENSDORF, S., LIVIERATOS, M. & DADA, N. 2017. Pigmentation Disorders: Diagnosis and Management. *American family physician*, 96.
- PRADEEP, A. R., RAO, N. S., NAIK, S. B. & KUMARI, M. 2013. Efficacy of varying concentrations of subgingivally delivered metformin in the treatment of chronic periodontitis: a randomized controlled clinical trial. *J Periodontol*, 84, 212-20.
- RAO, N. S., PRADEEP, A. R., KUMARI, M. & NAIK, S. B. 2013. Locally delivered 1% metformin gel in the treatment of smokers with chronic periodontitis: a randomized controlled clinical trial. *J Periodontol*, 84, 1165-71.
- RAVNBAK, M. & WULF, H. 2007. Pigmentation after single and multiple UV-exposures depending on UV-spectrum. *Archives of dermatological research*, 299, 25-32.

- RIVAS, S. & PANDYA, A. G. 2013. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. *Am J Clin Dermatol*, 14, 359-76.
- SARDANA, K. & GHUNAWAT, S. 2015. Rationale of using hypopigmenting drugs and their clinical application in melasma. *Expert review of clinical pharmacology*, 8, 123-134.
- SARMA, N., CHAKRABORTY, S., POOJARY, S. A., RATHI, S., KUMARAN, S., NIRMAL, B., FELICITA, J., SARKAR, R., JAISWAL, P. & D'SOUZA, P. 2017. Evidence-based review, grade of recommendation, and suggested treatment recommendations for melasma. *Indian dermatology online journal*, 8, 406.
- SEHGAL, V. N., VERMA, P., SRIVASTAVA, G., AGGARWAL, A. K. & VERMA, S. 2011. Melasma: treatment strategy. *J Cosmet Laser Ther*, 13, 265-79.
- SEIFARTH, C., SCHEHLER, B. & SCHNEIDER, H. J. 2013. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. *Exp Clin Endocrinol Diabetes*, 121, 27-31.
- SIADAT, A. H., IRAJI, F., BAHRAMI, R., NILFROUSHZADEH, M. A., ASILIAN, A., SHARIAT, S., NIKYAR, Z. & BOKAIE, S. 2016. The comparison between modified kligman formulation versus kligman formulation and intense pulsed light in the treatment of the post-burn hyperpigmentation. *Advanced biomedical research*, 5, 125-125.
- SKLAR, L. R., ALMUTAWA, F., LIM, H. W. & HAMZAVI, I. 2013. Effects of ultraviolet radiation, visible light, and infrared radiation on erythema and pigmentation: a review. *Photochemical & Photobiological Sciences*, 12, 54-64.
- SLOMINSKI, A. T., ZMIJEWSKI, M. A., ZBYTEK, B., TOBIN, D. J., THEOHARIDES, T. C. & RIVIER, J. 2013. Key role of CRF in the skin stress response system. *Endocr Rev*, 34, 827-84.

- STRATIGOS, A. J. & KATSAMBAS, A. D. 2005. The role of topical retinoids in the treatment of photoaging. *Drugs*, 65, 1061-1072.
- VASHI, N. A. & KUNDU, R. V. 2013. Facial hyperpigmentation: causes and treatment. *British Journal of Dermatology*, 169, 41-56.
- VIDEIRA, I. F. D. S., MOURA, D. F. L. & MAGINA, S. 2013. Mechanisms regulating melanogenesis. *Anais brasileiros de dermatologia*, 88, 76-83.

## LAMPIRAN

Lampiran 1. Hasil uji LSD nilai L\* antar kelompok

	<i>Base solusio</i>	Metformin 15%	Metformin 30%	UVB saja	Formula Kligman
<i>Base solusio</i>					
Metformin 15%	0.659				
Metformin 30%	0.627	0.354			
NB-UVB saja	0.112	0.249	<b>0.039*</b>		
Formula Kligman	0.138	0.055	0.316	<b>0.002*</b>	

Lampiran 2. Hasil uji LSD nilai b antar kelompok

	<i>Base solusio</i>	Metformin 15%	Metformin 30%	UVB saja	Formula Kligman
<i>Base solusio</i>					
Metformin 15%	<b>0.005*</b>				
Metformin 30%	0.650	<b>0.019*</b>			
NB-UVB saja	0.138	0.186	0.302		
Formula Kligman	0.341	<b>0.000*</b>	0.160	<b>0.015*</b>	

Lampiran 3. Hasil uji LSD nilai a antar kelompok

	<i>Base solusio</i>	Metformin 15%	Metformin 30%	Formula Kligman
<i>Base solusio</i>				
Metformin 15%	0.263			
Metformin 30%	0.291	<b>0.030*</b>		
NB-UVB saja	0.861	0.345		
Formula Kligman	<b>0.000*</b>	<b>0.000*</b>	<b>0.000*</b>	

Lampiran 4. Hasil uji LSD nilai  $\Delta E$  antar kelompok

	<i>Base solusio</i>	Metformin 15%	Metformin 30%	Formula Kligman
<i>Base solusio</i>				
Metformin 15%	<b>0.000*</b>			
Metformin 30%	0.119	<b>0.000*</b>		
Formula Kligman	<b>0.000*</b>	<b>0.000*</b>	<b>0.004*</b>	